Theriva Biologics is putting more of its eggs in the VCN-01 basket as it unveils a change-up in its R&D focus. | Theriva ...

Oncolytic virotherapy represents an innovative and promising approach for the treatment of cancer, including multiple myeloma (MM), a currently incurable plasma cell (PC) neoplasm. Despite the ...

Delytact (teserpaturev) is a genetically engineered oncolytic herpes simplex virus type 1 (HSV-1) that was approved for marketing in Japan earlier this year, and received pricing approval in ...

Theriva™ Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat ...

UroGen has issued $4m in ordinary shares to IconOVir. Credit: MacroEcon/Shutterstock. UroGen Pharma has broadened its oncology pipeline by acquiring IconOVir Bio’s assets related to the oncolytic ...

3月20日，浙江大学科研团队在国际顶级刊物Nature（《自然》）上又发表了两项重磅科研成果。浙江大学光电科学与工程学院/海宁国际联合学院狄大卫教授和赵保丹研究员团队研发的微米和纳米钙钛矿LED（micro-PeLED和nano-PeLED）达到了传 ...

UroGen Pharma has broadened its oncology pipeline by acquiring IconOVir Bio’s assets related to the oncolytic virus ICVB-1042. The company issued $4m in ordinary shares and additionally agreed ...

“The acquisition of ICVB-1042, a next-generation investigational oncolytic virus, marks a significant milestone in our plan to develop novel, locally administered therapies for bladder cancer ...

UroGen Pharma has opened another front in its attack on bladder cancer, paying IconOVir Bio $4 million in stock for an early-phase oncolytic virus that could work like a turbocharged Bacillus ...